ArticleJTCVS open2026
Increasing time-to-treatment for resectable non-small cell lung cancer: Predictors and survival impact.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify predictors of prolonged time-to-treatment initiation (TTI) among patients undergoing lung cancer surgery and determine whether this prolongation correspond to survival differences in resectable disease. Methods: We performed a retrospective cohort study of the National Cancer Database from 2018 to 2022. Patients with stage I-II non-small cell lung cancer were included; those with missing stage, treatment, or time-to-treatment data were excluded. Demographic, socioeconomic, clinical, treatment, and facility variables were analyzed. TTI was capped at 180 days to minimize outlier bias. Multivariable accelerated failure time models with gamma distribution were used to identify predictors of TTI prolongation. Survival was stratified by treatment initiation ≤30, 31 to 60, and >60 days. Results: Among eligible patients, mean TTI increased from 51.5 days in 2018 to 61.3 days in 2022. In stage I disease, Black patients experienced 13% longer TTI versus White patients (time ratio [TR], 1.13; 95% CI, 1.11-1.14). Nonprivate insurance status was associated with significantly longer TTI, including Medicaid coverage (TR, 1.22; 95% CI, 1.19-1.24). Treatment at different facilities also added 14% TTI (TR, 1.14; 95% CI, 1.13-1.15). In stage I and II disease, treatment initiation within 30 days demonstrated significantly superior overall survival compared with treatment after 60 days ( Conclusions: TTI for non-small cell lung cancer has progressively lengthened in recent years and disproportionately affects socioeconomically vulnerable patient groups. Prolongations in TTI are associated with inferior survival, underscoring the need for system-level interventions to improve coordination, access, and delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.